Aldosterone synthase inhibitors: a new option for antihypertensive, cardio-renal protection - PubMed
4 hours ago
- #hypertension
- #aldosterone synthase inhibitors
- #cardio-renal protection
- Aldosterone synthase inhibitors (ASIs), such as baxdrostat, lorundrostat, and vicadrostat, are new drugs that selectively inhibit aldosterone synthase with minimal effect on 11β-hydroxylase, showing promise for antihypertensive and organ-protective effects.
- Clinical trials indicate that reducing serum aldosterone levels by 50-70% with ASIs can lower blood pressure and provide organ protection, suggesting even small reductions may improve hypertension and related organ damage.
- ASI mechanisms differ from mineralocorticoid receptor antagonists (MRAs); ASIs lower aldosterone levels, potentially attenuating aldosterone actions in epithelial tissues without significantly affecting cortisol actions, while in non-epithelial tissues, cortisol is the primary ligand for MR.
- Although MRAs are well-established for antihypertensive and organ-protective benefits, clinical evidence for ASIs is still insufficient, necessitating future research to compare and optimize the use of both drug types.